Marc Kozin - Flex Pharma Non-Executive Independent Director
Director
Mr. Marc Kozin is an NonExecutive Independent Director of the company., since October 2014. Mr. Kozin was a Senior Advisor to L.E.K. Consulting, a global strategy consulting firm, since July 2011. Prior to that, Mr. Kozin served as president of L.E.K. North American practice for 15 years. Mr. Kozin currently serves as a member of the board of directors of UFP Technologies, Inc., DYAX Corporationration, Endocyte, Inc., OvaScience, Inc. and three privatelyheld companies. He also serves on the strategic advisory board for Healthcare Royalty Partners since 2014.
| Age | 56 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 617 874-1821 |
| Web | www.flex-pharma.com |
Flex Pharma Management Efficiency
The company has return on total asset (ROA) of (61.9171) % which means that it has lost $61.9171 on every $100 spent on assets. This is way below average. Flex Pharma's management efficiency ratios could be used to measure how well Flex Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Juan Cerda | Meli Hotels International | N/A | |
| Lucier Gregory | Catalent | 50 | |
| Melvin Booth | Catalent | 73 | |
| Fernando Silva | Meli Hotels International | N/A | |
| Gregory Lucier | Catalent | 56 | |
| Kevin Kotler | Avadel Pharmaceuticals PLC | 45 | |
| Francisco Garcia | Meli Hotels International | N/A | |
| Christophe Navarre | Avadel Pharmaceuticals PLC | ||
| Luis Terminel | Meli Hotels International | 71 | |
| Uwe Rohrhoff | Catalent | 56 | |
| Michael Barber | Catalent | 60 | |
| John Greisch | Catalent | 65 | |
| William Johnson | Biglari Holdings | 71 | |
| Madhavan Balachandran | Catalent | 69 | |
| Guillaume Cerutti | Avadel Pharmaceuticals PLC | 49 | |
| Francis Fildes | Avadel Pharmaceuticals PLC | 71 | |
| Carina Lazaro | Meli Hotels International | N/A | |
| Juan Mora | Meli Hotels International | 75 | |
| James Quella | Catalent | 68 | |
| Jack Stahl | Catalent | 67 | |
| Christa Kreuzburg | Catalent | 61 | |
Management Performance
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -61.92 |
Flex Pharma Leadership Team
Elected by the shareholders, the Flex Pharma's board of directors comprises two types of representatives: Flex Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Flex. The board's role is to monitor Flex Pharma's management team and ensure that shareholders' interests are well served. Flex Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Flex Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Cermak, Vice President - Research & Development | ||
| Roderick MacKinnon, Co-Founder, Co-Chair of Scientific Advisory Board and Director | ||
| Marc Kozin, Non-Executive Independent Director | ||
| Christoph Westphal, Chairman of the Board and Presidentident, CEO | ||
| William McVicar, Interim President Interim CEO | ||
| Michelle Stacy, Director | ||
| Marina Hahn, President of Consumer | ||
| Robert Perez, Director | ||
| John McCabe, VP of Fin. and Treasurer | ||
| Robert Hadfield, General Counsel, Secretary | ||
| Kathie Lindemann, COO | ||
| Elizabeth Woo, Senior Vice President Investor Relations and Corporate Communications | ||
| Roger Tung, Director | ||
| John Sculley, Non-Executive Independent Director | ||
| Stuart Randle, Non-Executive Independent Director | ||
| Jeffrey Capello, Director | ||
| Thomas Wessel, Chief Medical Officer | ||
| Peter Hutt, Non-Executive Independent Director |
Flex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Flex Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -61.92 | |||
| Profit Margin | (293.80) % | |||
| Operating Margin | (771.45) % | |||
| Current Valuation | 4.45 M | |||
| Shares Outstanding | 18.07 M | |||
| Shares Owned By Insiders | 13.44 % | |||
| Shares Owned By Institutions | 11.68 % | |||
| Number Of Shares Shorted | 748.99 K | |||
| Price To Earning | (1.35) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Flex Stock
If you are still planning to invest in Flex Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Flex Pharma's history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |